Tradestie Institutional Equity Comparison Engine
PLUR vs CLYM โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
CLYM Overall Edge
CLYM Captures Institutional Edge (2โ1 Pillars ยท 6โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Climb Bio, Inc. Common Stock (CLYM) driven by superior Growth & Margin, Momentum & Technical while PLUR counters with relative strength in Valuation. Fundamentally, PLUR trades at 3.6x Forward P/E with -2454.5% operating margin (-15.8% YoY revenue) versus CLYM at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, PLUR sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against CLYM sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
PLUR
PLUR 3.6x vs CLYM N/M Fwd P/E
Growth & Margin Winner
CLYM
Op Margin -2454.5% vs 0.0% ยท YoY -15.8% vs +0.0%
Momentum & Technical Winner
CLYM
1Y -78.8% vs +407.4% ยท 52W Pos 2% vs 48%
Options & Structure Winner
Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
PLUR
US Equity
Pluri Inc.
Biological Products, (No Diagnostic Substances)
$0.94
-9.19% 1D
Market Cap
$15.1M
1M Return
+11.09%
1Y Return
-78.78%
Forward P/E
3.6x
Unified AI Score
28.8 / 100
SELL
Tech 15.0
Fund 34.0
Flow 50.0
Mom 40.0
CLYM
NASDAQ
Climb Bio, Inc. Common Stock
Pharmaceutical Preparations
$9.64
-3.02% 1D
Market Cap
$608.5M
1M Return
-0.92%
1Y Return
+407.37%
Forward P/E
N/M
Unified AI Score
45.7 / 100
HOLD
Tech 41.0
Fund 47.0
Flow 50.0
Mom 54.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
PLUR -78.78%
CLYM +407.37%
Spread: +482.9 pp (CLYM Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
PLUR TTM Op. Margin: -2454.5%
CLYM TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on PLUR vs CLYM. Trailing 12-month operating profitability (PLUR -2454.5% vs CLYM 0.0%) and valuation multiples (PLUR 3.6x vs CLYM N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | PLUR | CLYM | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $15.1M | $608.5M | Larger Scale | CLYM |
| Trailing P/E Ratio Valuation | 3.6x | N/M | Lower Multiple | PLUR |
| Forward P/E Ratio Valuation | 3.6x | N/M | Lower Multiple | PLUR |
| Revenue Growth (YoY) Growth | -15.8% | +0.0% | Higher Growth | CLYM |
| Operating Margin (TTM) Profitability | -2454.5% | 0.0% | Higher Margin | CLYM |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -1022.0% | -29.3% | Higher ROE | CLYM |
| 52-Week Range Position Momentum | 2% ($1โ$5) | 48% ($2โ$18) | Stronger Trend | CLYM |
| Beta / 30D Volatility Risk Regime | 0.80ฮฒ ยท 102% Vol | 1.52ฮฒ ยท 112% Vol | Lower Realized Risk | PLUR |
| Unified Institutional Score Composite Signal | 28.8 / 100 (SELL) | 45.7 / 100 (HOLD) | Higher Composite | CLYM |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full PLUR vs CLYM Buy Guide
PLUR
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
CLYM
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither PLUR nor CLYM registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.